Journal Article

Anaemia management and cardiomyopathy in renal failure

Rosemary L. Donne and Robert N. Foley

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue suppl_1, pages 37-40
Published in print January 2002 | ISSN: 0931-0509
Published online January 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.suppl_1.37
Anaemia management and cardiomyopathy in renal failure

Show Summary Details

Preview

Patients with renal failure are at great cardiovascular risk, with attributable death rates 10–20 times those of an age‐matched population. Most patients develop cardiomyopathy, with a continuum of left ventricular dilation (LV), hypertrophy and systolic dysfunction. Untreated, these conditions predispose to cardiac failure, a dominant and highly lethal cardiovascular syndrome in this population. Several prospective observational studies have demonstrated anaemia to be an independent risk factor for each step in the process: haemodynamic overload, maladaptive LV enlargement, LV burn‐out and death. Recent evidence suggests that physiological haemoglobin targets (e.g. >12 g/dl) may be optimal for maintaining cardiac health and quality of life, especially in patients without pre‐existing clinical cardiac disease. Ongoing studies should determine whether a physiologically targeted approach to anaemia management reduces the burden of cardiomyopathy in renal failure.

Keywords: anaemia; cardiac disease; chronic kidney disease; epoetin; haemoglobin

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.